Compare Abbott Laboratories (ABT) vs First Solar, Inc. (FSLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs First Solar, Inc. — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while First Solar, Inc. trades at $226.26 (market cap $24.47B). The key difference: Abbott Laboratories is far larger — about 6.8× First Solar, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| ABT | FSLR | |
|---|---|---|
Market Cap | $166.94B | $24.47B |
Sector | Health | Technology |
52-Week High | $136.62 | $318.30 |
52-Week Low | $82.57 | $160.84 |
Enterprise Value | $193.69B | $22.63B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
First Solar (FSLR) trades at $227.72, up 1.4% with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with $5.22B revenue, 30.73% net margin, and positive cash flow trends. Recent earnings beat expectations in Q1 2026 but missed in previous quarters. Multiple class action lawsuits create significant headwinds, though Deutsche Bank recently upgraded the stock citing valuation discount.
The stock presents a valuation opportunity with P/E of 15.06 below industry averages, but legal risks and technical weakness suggest cautious optimism. Analyst consensus price target of $272.20 implies 19.5% upside potential, though investors must weigh strong profitability against ongoing litigation concerns and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
